6月4日,百利天恒(688506)发布公告,公司自主研发的创新生物药注射用BL-M05D1(Claudin18.2ADC)用于在既往经一线治疗的Claudin18.2阳性晚期胃癌或胃食管结合部腺癌的III期临床试验已完成首例受试者入组。 注射用BL-M05D1是与iza-bren共享同一“连接子+毒素”平台的ADC药物,目前正在国内外开展3项临床试验,其中包括1个III期、1个Ib期及1个Ia期...
Source Link6月4日,百利天恒(688506)发布公告,公司自主研发的创新生物药注射用BL-M05D1(Claudin18.2ADC)用于在既往经一线治疗的Claudin18.2阳性晚期胃癌或胃食管结合部腺癌的III期临床试验已完成首例受试者入组。 注射用BL-M05D1是与iza-bren共享同一“连接子+毒素”平台的ADC药物,目前正在国内外开展3项临床试验,其中包括1个III期、1个Ib期及1个Ia期...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.